Comparison of in vivo acute stent recoil between the bioabsorbable everolimus‐eluting coronary stent and the everolimus‐eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials

Tanimoto, Shuzou; Serruys, Patrick W.; Thuesen, Leif; Dudek, Dariusz; Bruyne, Bernard De; Chevalier, Bernard; Ormiston, John A.

doi:10.1002/ccd.21136

Cited by 139 publications

(95 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Tanimoto et al 9 compararam o SVB com o EES e constataram que o percentual de retração aguda foi de 6,9 ± 7,0% no grupo SVB e 4,3 ± 7,1% no grupo EES (P = 0,25). Onuma et al 10 compararam a retração aguda de duas versões do SVB ABSORB (revision 1.0 e revision 1.1) com o stent XIENCE ® V e descobriram que a retração aguda do SVB 1.1 foi um pouco maior do que os EES metálicos (EES: 4,3 ± 7,1%; SVB 1.0: 6,9 ± 7,0%; SVB 1.1: 6,7 ± 6,4%; P = 0,22).…”

Section: Discussionunclassified

Comparação da retração aguda do stent entre o suporte vascular bioabsorvível eluidor de everolimus e dois diferentes stents metálicos farmacológicos

Borghi¹,

Costa²,

Abizaid³

et al. 2013

Rev. Bras. Cardiol. Invasiva

View full text Add to dashboard Cite

Section: Discussionunclassified

Comparação da retração aguda do stent entre o suporte vascular bioabsorvível eluidor de everolimus e dois diferentes stents metálicos farmacológicos

Borghi¹,

Costa²,

Abizaid³

et al. 2013

Rev. Bras. Cardiol. Invasiva

View full text Add to dashboard Cite

“…In particular, the ABSORB cohort A trial, using BVS revision 1.0, demonstrated a slightly higher acute recoil with BVS than with metallic stents. 67 More recently, Onuma et al 68 showed that, among 88 patients enrolled in the ABSORB cohort B trial, absolute recoil of BVS 1.1 was numerically higher than that of metallic EES and similar to that of BVS 1.0, but the differences did not reach statistical significance. In their multivariate regression model, high absolute recoil was predicted by high balloon/artery ratio.…”

Section: Disclosuresmentioning

confidence: 99%

“…Of note, the stent/scaffold type was not a predictor of acute recoil. 67 Finally, a recent study 69 analyzing clinical data from the first 450 patients enrolled in ABSORB EXTEND has demonstrated low rates of ischemia-driven MACE (4.2%) and target vessel failure (4.7%) at 12 months. Of note, the cases of device failure were principally caused by dislodgement (0.67%) and to late scaffold thrombosis (0.89%).…”

Section: Disclosuresmentioning

confidence: 99%

ST-Segment Elevation Myocardial Infarction

Scalone

Brugaletta

Gómez-Monterrosas

et al. 2015

Circ J

View full text Add to dashboard Cite

Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp BVS as compared with metallic platform DES may include: decrease in late adverse events through complete biodegradation of stent struts preventing the risk of thrombus formation at the site of impaired endothelialization; normalization of vasomotion and compensatory remodeling during follow-up, thus suggesting restoration of normal vessel physiology after complete biodegradation of the stent struts; no interference with diagnostic or therapeutic measures (eg, coronary artery bypass graft) in case of disease progression; improved vascular healing; and discontinuation of long-term antiplatelet therapy in patients with single-vessel coronary artery disease. In particular, some crucial points in STEMI patients have to be emphasized. First of all, culprit lesions are frequently localized in the proximal segments of the coronary artery tree; restoration of physiological vasomotion may therefore have a greater effect in patients with STEMI as compared with patients with stable coronary artery disease. Secondly, vulnerable plaque of STEMI lesions, often characterized by necrotic core, interferes with vascular healing after metallic stent implantation, thus leading to coronary evagination or late acquired malapposition, both of which have been correlated with adverse ischemic outcomes. 14 Recent study suggests that BVS may eventually decrease the incidence of angina during follow-up, by reducing fixed and dynamic restenoses and by improving vasomotor responses. 15 Finally, the potential advantages of implanting BVS (vs. other DES) in STEMI may be mostly related to the young age of these patients. Indeed, they usually have less extensive coronary artery disease (compared with non-STrimary percutaneous coronary intervention (PCI) currently represents the first choice of treatment in experienced centers for patients presenting with ST-segment elevation myocardial infarction (STEMI) with limited time delay. 1 In this context, first-generation drug-eluting stents (DES) have reduced the need for repeat revascularization compared with bare metal stents (BMS). 2-4 However, the 1st-generation DES have been associated with late complications, such as neo-atherosclerosis, late restenosis, and stent thrombosis. 5 In particular, in the acute thrombotic setting, the antiproliferative drug elution used in DES has been shown to interfere with vascular healing processes, creating the background for delayed strut coverage, and persistent or acquired malapposition. 6,7 Possible explanations for this phenomenon are thrombus sequestration behind the struts, which subsequently resolves with acquired malapposition, and vasoconstriction during the acute phase. 8 The newer-generation DES with improved biocompatibility of polymers have also shown a lower rate of clinical events in acute patients as compared with either 1st-generation DES or BMS. 9-12 The clinical introduction of bioresorbable scaffolds resulted in a revolutionary change among local c...

show abstract

“…Encouragingly, studies also indicated that the BVS has comparable acute vessel recoil to the EES, inferring similar initial radial strength. 56, 57 Although the scaffold is radiolucent, 2 platinum markers at each end allow easy visualization on angiography and other imaging modalities.…”

Section: Onuma Y Et Almentioning

confidence: 99%

Bioresorbable Scaffold Technologies

Onuma

Ormiston

Serruys

2011

Circ J

Self Cite

106

View full text Add to dashboard Cite

Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp he application of bioresorbable devices has previously been tested in multiple medical fields, such as stenting of pediatric pulmonary artery stenosis, 1 management of recurrent benign strictures of the esophagus, 2 treatment of coronary artery stenosis 3-6 and peripheral artery disease (Igaki-Tamai stent, see later). Within the field of interventional cardiology, percutaneous coronary intervention (PCI) with fully bioresorbable scaffold (BRS) devices have recently attracted great interest. Since BRS devices aim to provide temporary mechanical support to the vessel wall and subsequently disappear, the technology has the potential to overcome many of the safety concerns associated with metallic drug-eluting stents (DES), and possibly even convey further clinical benefit. Although the technology is still in its infancy, several devices have been tested in clinical trials and the initial results have been very promising.This review will discuss the emerging need for BRS, the theoretical advantages of this new technology over current generation metallic DES and review the status of the currently available BRS. In addition, we will discuss the ideal duration of bioresorption, the proven and potential clinical benefits, and future perspective of this rapidly progressing technology. The Emerging Need for Fully Bioresorbable Scaffold:Historical PerspectiveInvention of balloon angioplasty in 1977 by Andreas Gruntzig was a huge leap forward in the treatment of obstructive coronary artery disease, and was undoubtedly the 1st revolution in interventional cardiology. However, the mode of treatment was limited by risks of acute occlusion in the treated vessel as well as frequent restenosis, which occurred in approximately 30% to 40% of lesions after angioplasty. 20 However, this early enthusiasm with metallic DES has been tempered in recent years by widespread concerns regarding the safety of DES with respect to acute, late and very late stent thrombosis. Registries of all-comers treated with DES demonstrated rates of late stent thrombosis of 0.53% per year, with a continued increase to 3% over 4 years. 21, 22 In patients with complex multivessel disease, the rate of combined definite, probable and possible stent thrombosis was as high as 9.4% at 5 years Fully bioabsorbable scaffolds (BRS) are a novel approach that provides transient vessel support with drug delivery capability without the long-term limitations of the metallic drug-eluting stents (DES), such as permanent caging with or without malapposition. The technology has the potential to overcome many of the safety concerns associated with metallic DES, and possibly even convey further clinical benefit. Although the technology is still in its infancy, several devices have been tested in clinical trials and the initial results have been very promising. This review will discuss the emerging need for BRS, the theoretical advantages of this new technology over current generati...

show abstract

Comparison of in vivo acute stent recoil between the bioabsorbable everolimus‐eluting coronary stent and the everolimus‐eluting cobalt chromium coronary stent: Insights from the ABSORB and SPIRIT trials

Abstract: In vivo acute stent recoil of the BVS is slightly larger but insignificantly different from that of the EES, implying that the BVS may have good radial strength similar to the metallic stent.

Cited by 139 publications

References 22 publications

Comparação da retração aguda do stent entre o suporte vascular bioabsorvível eluidor de everolimus e dois diferentes stents metálicos farmacológicos

Comparação da retração aguda do stent entre o suporte vascular bioabsorvível eluidor de everolimus e dois diferentes stents metálicos farmacológicos

ST-Segment Elevation Myocardial Infarction

Bioresorbable Scaffold Technologies

Contact Info

Product

Resources

About